MENU
INAB
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
IN8bio (INAB) Ownership - Who owns IN8bio?
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells... Show more
Profile
Industry
N/A
Address
350 5th Avenue
Phone
+1 646 600-6438
Employees
31
Web
https://www.in8bio.com
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
7.37M
P/E Ratio
N/A
Total Cash
11.89M
Projected Growth
N/A
Total Debt
4.27M
Revenue
N/A
Risk (Beta)
0.05
Dividend Yield
N/A
Total Cash/Share
3.45
Total Debt/Equity
N/A
Revenue/Share
null USD as % of share price
Fundamentals
INAB
Capitalization
7.37M
P/E Ratio
N/A
Risk (Beta)
0.05
Dividend Yield
N/A
Total Cash
11.9M
Total Cash/Share
3.45
Total Debt
4.27M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0%
Revenue
0
ROE
N/A
Book Value
13.9M
P/B Ratio
0.53
Cash Flow
N/A
Earnings
-13.2
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
8K
Current Ratio
4.30
Current Revenue Per Employee
N/A
Dividends Per Share - Security
N/A
EBITDA
-23.92M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-120.77
Shares Held By Institutions
4.85M
Shares Outstanding - Current
3.44M
Total Liabilities
5.99M
Total Volume MTD
N/A
Value
1
Gain YTD
-72.395
View a ticker or compare two or three
VS
VS
Show more...
Interact to see
Advertisement
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information
General Information
Industry Biotechnology
Profile
Fundamentals
Details
Industry
N/A
Address
350 5th Avenue
Phone
+1 646 600-6438
Employees
31
Web
https://www.in8bio.com